These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 12187169)

  • 41. Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients.
    Warren JL; Mariotto A; Melbert D; Schrag D; Doria-Rose P; Penson D; Yabroff KR
    Med Care; 2016 Aug; 54(8):e47-54. PubMed ID: 24374419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Information gained from linking SEER Cancer Registry Data to state-level hospital discharge abstracts. Surveillance, Epidemiology, and End Results.
    Brooks JM; Chrischilles E; Scott S; Ritho J; Chen-Hardee S
    Med Care; 2000 Nov; 38(11):1131-40. PubMed ID: 11078053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer.
    Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
    J Geriatr Oncol; 2019 Sep; 10(5):705-708. PubMed ID: 30795923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.
    Healy MA; Morris AM; Abrahamse P; Ward KC; Kato I; Veenstra CM
    BMC Cancer; 2018 Apr; 18(1):481. PubMed ID: 29703172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.
    Edwards BK; Brown ML; Wingo PA; Howe HL; Ward E; Ries LA; Schrag D; Jamison PM; Jemal A; Wu XC; Friedman C; Harlan L; Warren J; Anderson RN; Pickle LW
    J Natl Cancer Inst; 2005 Oct; 97(19):1407-27. PubMed ID: 16204691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing comorbidity using claims data: an overview.
    Klabunde CN; Warren JL; Legler JM
    Med Care; 2002 Aug; 40(8 Suppl):IV-26-35. PubMed ID: 12187165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.
    Pfister DG; Rubin DM; Elkin EB; Neill US; Duck E; Radzyner M; Bach PB
    JAMA Oncol; 2015 Dec; 1(9):1303-10. PubMed ID: 26448610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data.
    Wang PS; Walker A; Tsuang M; Orav EJ; Levin R; Avorn J
    J Clin Epidemiol; 2000 Jun; 53(6):571-8. PubMed ID: 10880775
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world lessons: combining cancer registry and retail pharmacy data for oral cancer drugs.
    Howlader N; Lund JL; Enewold L; Stevens J; McNeel T; Rivera D; Mariotto A; Cronin KA
    J Natl Cancer Inst Monogr; 2024 Aug; 2024(65):162-167. PubMed ID: 39102884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
    JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.
    Warren JL; Klabunde CN; Schrag D; Bach PB; Riley GF
    Med Care; 2002 Aug; 40(8 Suppl):IV-3-18. PubMed ID: 12187163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The sensitivity of Medicare claims data for case ascertainment of six common cancers.
    Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
    Med Care; 1999 May; 37(5):436-44. PubMed ID: 10335746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Medicare data to identify incident breast cancer cases.
    Warren JL; Riley GF; McBean AM; Hakim R
    Health Care Financ Rev; 1996; 18(1):237-46. PubMed ID: 10165033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.
    Eaton AA; Sima CS; Panageas KS
    J Natl Compr Canc Netw; 2016 Jan; 14(1):57-65. PubMed ID: 26733555
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An approach to identifying incident breast cancer cases using Medicare claims data.
    Freeman JL; Zhang D; Freeman DH; Goodwin JS
    J Clin Epidemiol; 2000 Jun; 53(6):605-14. PubMed ID: 10880779
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variation in chemotherapy utilization in ovarian cancer: the relative contribution of geography.
    Polsky D; Armstrong KA; Randall TC; Ross RN; Even-Shoshan O; Rosenbaum PR; Silber JH
    Health Serv Res; 2006 Dec; 41(6):2201-18. PubMed ID: 17116116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly.
    Engels EA; Pfeiffer RM; Ricker W; Wheeler W; Parsons R; Warren JL
    Am J Epidemiol; 2011 Oct; 174(7):860-70. PubMed ID: 21821540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does reimbursement influence chemotherapy treatment for cancer patients?
    Jacobson M; O'Malley AJ; Earle CC; Pakes J; Gaccione P; Newhouse JP
    Health Aff (Millwood); 2006; 25(2):437-43. PubMed ID: 16522584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service.
    Schenck AP; Klabunde CN; Warren JL; Peacock S; Davis WW; Hawley ST; Pignone M; Ransohoff DF
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):799-804. PubMed ID: 18381471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.